Neuropsychiatry

Explore the complex interplay of genetics, environment, concussion, substance abuse, and inflammation in severe mental illnesses, revealing critical insights for prevention and treatment.

Leqembi for the treatment of Alzheimer disease has been launched in Austria on August 25, 2025, and will be launched in Germany on September 1, 2025—the first launches in the EU.

New research highlights lithium's crucial role in brain health, revealing its potential to combat Alzheimer disease and enhance mental wellness.

Antidepressant treatment for late-life depression enhances cognitive functions like memory and learning, linking symptom relief to cognitive improvement.

The complexities of Huntington disease can pose challenges for diagnosis. Let's take a look at its neuropsychiatric symptoms and the need for comprehensive treatment strategies.

Biogen's zuranolone gains positive opinion for treating postpartum depression, promising rapid symptom relief and potential EU approval by 2025.

Anavex Life Sciences reveals significant cognitive and functional improvements in early Alzheimer disease patients using blarcamesine, highlighting its potential as a long-term treatment.

The FDA has cleared the IND application for MIRA Pharmaceuticals' Ketamir-2, a promising oral treatment for neuropathic pain, which has shown superior efficacy and safety in preclinical studies.

Cognition Therapeutics reveals promising phase 2 results for zervimesine in treating dementia with Lewy bodies and Alzheimer disease at AAIC 2025.

Roche unveils promising Alzheimer disease treatments and diagnostic tools, including trontinemab and the Elecsys pTau217 blood test, at the AAIC conference.

Researchers uncover a novel biomarker for major depressive disorder, linking regional homogeneity in fMRI to decreased cerebral blood flow and symptom severity.

In this CME article, learn more about the complexities of neuropsychiatric symptoms in Parkinson disease, including psychosis and cognitive impairment, and effective treatment strategies.

Explore the complex role of dopamine in schizophrenia, its impact on symptoms, and potential therapeutic advancements.

May is American Stroke Month. Here, you can find important information about recognizing the signs of the stroke to share with patients.

Combination therapy of TMS and ketamine could enhance brain perfusion and neuroplasticity.

Research reveals that IV haloperidol and ziprasidone are safe for treating delirium in patients that are critically ill, showing minimal impact on QTc intervals.

Explore effective strategies for dementia risk reduction and understand the importance of early cognitive assessments in aging adults.

In this CME article, explore the complexities of Parkinson disease, focusing on neuropsychiatric symptoms, their prevalence, and effective treatment strategies for improved patient care.

In this CME article, learn more about the common neuropsychiatric sequelae of post-acute sequelae of COVID-19, the underlying neurobiological mechanisms, and evidence-based treatments and interventions.

The prevalence of tobacco use in schizophrenia is over 60%—3 times that of the general population. However, the reason for the high prevalence of tobacco use in schizophrenia remains largely unknown.

Learn more about key findings on sex differences in cognition, exploring the possible causes and implications for clinical practice.

Disruptions to cognitive control, as well as to emotional processes, are implicated in a wide range of psychiatric disorders.

Cognitive symptoms affect between 85% and 94% of patients with major depressive disorder. Despite this prevalence, cognitive dysfunction often remains undertreated and inadequately addressed in routine clinical practice.

Given that individual differences exist regarding the effects of brain injury and gaps persist in the treatment continuum, challenges arise in treating individuals with acquired brain injury. Addressing these challenges can improve patient outcomes.

A new trial is testing a first-of-its-kind stem cell therapy for Parkinson disease, using a patient’s own reprogrammed cells to restore lost dopamine function.

Neurocrine Biosciences has initiated a phase 1 clinical study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of NBI-1140675 for certain neurological and neuropsychiatric conditions, such as tardive dyskinesia.

Frontal lobe syndrome can present with a range of perseverative, disinhibited, overactive behaviors that do not meet traditional dementia/neurocognitive disorder criteria. Learn more here.

Because diagnosis and management of concussions remain challenging, reliable biomarkers can improve effective intervention.

The lates update in lecanemab’s journey: the FDA has accepted the BLA for lecanemab-irmb subcutaneous autoinjector for weekly maintenance dosing.